Stock Events

Stock Events

Biofrontera 

€0.000000
58
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7AugExpected
Q1 2023
Q1 2026
Next
-0.35
-0.26
-0.18
-0.09
Expected EPS
-0.09184034999999999
Actual EPS
N/A

Financials

-25.63%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
36.13MRevenue
-9.26MNet Income

Analyst Ratings

2.28Average Price Target
The highest estimate is 2.28.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AI1.MU. It's not an investment recommendation.
Apple
8
AAPL
NVIDIA
8
NVDA
AMD
8
AMD
Tesla
7
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Davis Select U.S. Equity
DUSA
Mkt Cap0
DUSA Pharmaceuticals, Inc. is a direct competitor in the dermatology space, specifically in photodynamic therapy products, similar to Biofrontera's Ameluz for treating actinic keratosis.
Merck
MRK
Mkt Cap319.99B
Merck & Co., Inc. has a diversified portfolio that includes treatments for various conditions, including skin-related diseases, potentially competing with Biofrontera's dermatological products.
Pfizer
PFE
Mkt Cap138.61B
Pfizer Inc. is a global pharmaceutical company with a broad product line that includes treatments for skin conditions, making it a competitor to Biofrontera.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson offers a wide range of healthcare products, including pharmaceuticals and personal care products for skin health, competing with Biofrontera's dermatological treatments.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie Inc., having acquired Allergan, has strengthened its dermatology portfolio, making it a stronger competitor to Biofrontera in the skin care and treatment market.
Novartis
NVS
Mkt Cap305.1B
Novartis International AG has a significant presence in the dermatology market with products that treat a range of skin conditions, competing with Biofrontera's therapeutic offerings.

About

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Show more...
CEO
Dr. Hermann Luebbert Ph.D.
Employees
88
Country
United States
ISIN
US09077D1000

Listings

XNAS
US
BFRI
MU
DE
B8FK.MU
MU
DE
AI1.MU
STU
DE
AI10.STU

0 Comments

Share your thoughts

FAQ

What is Biofrontera stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Biofrontera stocks are traded under the ticker AI1.MU.
When is the next Biofrontera earnings date?▼
Biofrontera is going to release the next earnings report on August 07, 2026.
What were Biofrontera earnings last quarter?▼
AI1.MU earnings for the last quarter are -0.35 EUR per share, whereas the estimation was -0.1 EUR resulting in a -256.52% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Biofrontera revenue for the last year?▼
Biofrontera revenue for the last year amounts to 36.13M EUR.
What is Biofrontera net income for the last year?▼
AI1.MU net income for the last year is -9.26M EUR.
How many employees does Biofrontera have?▼
As of July 10, 2026, the company has 88 employees.
In which sector is Biofrontera located?▼
Biofrontera operates in the Health & Wellness sector.
When did Biofrontera complete a stock split?▼
Biofrontera has not had any recent stock splits.
Where is Biofrontera headquartered?▼
Biofrontera is headquartered in Woburn, United States.